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and Aortic Stenosis
Biomarker or New Target for an Old Foe?*Donald Heistad, MD,yzx Hardik Doshi, MD, MPHyThese are certain signs to know
Faithful friend from ﬂattering foe.
—William Shakespeare, Sonnets to
Sundry Notes of Music. VI (1)T here has been great progress in treatment ofaortic stenosis, with development of pros-thetic, bioprosthetic, and percutaneous pros-
thetic valves. A medical treatment for aortic stenosis,
however, remains elusive.
In these comments, we consider 2 questions. In ad-
dition to being a biomarker, is lipoprotein-associated
phospholipase A2 (LpPLA2) a promising target to
slow progression of aortic stenosis? In light of evi-
dence that inhibitors of LpPLA2 are ineffective in
acute coronary syndrome or stable ischemic heart
disease, what makes aortic stenosis a more promising
target?
Analysis of a subgroup of the prospective, ran-
domized PROGRESSA (Metabolic Determinants Of
The Progression Of Aortic Stenosis) study (2) suggests
that, in patients with mild (but not moderate/severe)
aortic stenosis, plasma LpPLA2 activity is predictive
of rate of progression of aortic stenosis. One impli-
cation of the ﬁnding is that LpPLA2 may be useful as a
predictor of patients that may be at greatest risk of
developing severe aortic stenosis, and therefore may
be appropriate for an experimental treatment.
Another implication, which is not as well founded, is
that LpPLA2 may be a therapeutic target in patients
with mild aortic stenosis. This latter possibility can be
viewed as high risk/high gain.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yDepartment of Internal Medicine, University of Iowa College of
Medicine, Iowa City, Iowa; zDepartment of Pharmacology, University
of Iowa College of Medicine, Iowa City, Iowa; and the xDepartment of
Molecular, Cellular, and Developmental Biology, University of Colorado,
Boulder, Colorado. Both authors have reported that they have no
relationships relevant to the contents of this paper to disclose.An appropriate question relates to biologic plausi-
bility: is LpPLA2 involved in development and pro-
gression of aortic stenosis? If so, it is an attractive
target for treatment. If not, its potential role is limited
to a biomarker.
LPPLA2 AS A BIOMARKER
The West of Scotland Coronary Prevention Study
Group suggested that LpPLA2 is associated with
atherosclerotic vascular disease (3). LpPLA2 is an en-
zyme expressed by inﬂammatory cells in atheroscle-
rotic plaques, and is found in the circulation bound
to low-density lipoprotein cholesterol (LDL), high-
density lipoprotein cholesterol, and lipoprotein(a) (4).
The possibility that LpPLA2 might be causally
related to atherosclerosis, and perhaps unstable pla-
ques, was supported by treatment with an LpPLA2
in a porcine experimental model (5). Because lyso-
phospholipids are chemoattractants, an inhibitor of
LpPLA2 might be protective. On the other hand, be-
cause LpPLA2 may be protective, by converting a
toxic phospholipid to a lysophospholipid, an inhibitor
of LpPLA2 may be harmful. Several trials indicate that
LpPLA2 is a disappointing target for treatment of
acute coronary syndrome and stable ischemic heart
disease (6–8).
In the STABILITY trial, darapladib (an inhibitor of
Lp-PLA2) failed to reduce the risk of death,
myocardial infarction, or stroke in patients with
stable coronary artery disease (6). Similarly, in the
SOLID-TIMI 52 trial, darapladib failed to reduce the
risk of major coronary events in patients with recent
acute coronary syndrome (7). In the VISTA-16 trial,
varespladib, an inhibitor of secretory Lp-PLA2,
increased the risk of myocardial infarction in pa-
tients with recent acute coronary syndrome, leading
to early termination of the trial (8). The failure of
these inhibitors to improve cardiovascular outcomes
reﬂects gaps in our knowledge of the pathobiology of
Lp-PLA2.
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35LPPLA2 IN AORTIC STENOSIS
In this issue of iJACC, Capoulade et al. (2) report
that higher plasma Lp-PLA2 activity is associated
with more rapid progression of aortic stenosis, as
measured by Doppler echocardiography (Figure 1).
This effect was noted only in the subset of patients
with mild stenosis (deﬁned as peak aortic jet
velocity <3.0 m/s) at baseline. Thus, Lp-PLA2 was a
marker of progression of aortic stenosis, and the au-
thors suggested that it should be considered as a
target for clinical trials in patients with mild aortic
stenosis.FIGURE 1 Schematic of a Leaﬂet of the Aortic Valve
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that is expressed by
inﬂammatory cells. LpPLA2 is carried in the circulation predominately bound to low-density
lipoprotein (LDL)þPLA2 and to Lp(a)[Lp(a)þPLA2]. LDL and Lp(a) undergo oxidation by
reactive oxygen species (ROS) in the aortic valve. These oxidized phospholipids (OxPLs) are
subsequently converted to lysophosphatidylcholine (LPC) and oxidized nonesteriﬁed fatty
acids (OxNEFA), both of which are chemoattractants that recruit monocytes to the valve.
Activated monocytes/macrophages release secretory phospholipase A2 (s-PLA2), which
promotes further breakdown of OxPLs to chemoattractants. LPC is also a stimulus for
calciﬁcation of valve interstitial cells (VICS). The ﬁgure shows targets of darapladib, an
Lp-PLA2 inhibitor used in the SOLID-TIMI 52 and STABILITY trials, and varespladib (s-PLA2
inhibitor), used in the VISTA-16 trial. Lp(a) ¼ lipoprotein(a); SOLID-TIMI 52 ¼ The Stabi-
lization Of plaques using Darapladib-Thrombolysis In Myocardial Infarction 52;
STABILITY ¼ Stabilization of Atherosclerotic plaque by initiation of darapladib therapy;
VISTA-16 ¼ Vascular Inﬂammation Suppression to Treat Acute coronary syndrome-16.
SEE PAGE 26In light of failure of several trials in relation to
coronary heart disease, why is there reason to suggest
that aortic stenosis may be more amenable to reduc-
tion of LpPLA2? There are several differences between
blood vessels and the aortic valve (2,9), which may
predict a different role for LpPLA2. The differences
between blood vessels and the aortic valve reduce
the predictive value of trials in vascular disease.
The authors focus on calciﬁcation of the aortic
valve as the predominant mechanism for stenosis.
This assumption is far from conclusive. In patients,
calciﬁcation may not be associated with severity of
aortic stenosis (10). We have suggested that the term
“ﬁbrocalciﬁc aortic valve stenosis” may be more ac-
curate than calciﬁc aortic stenosis (11), because it
is not clear whether ﬁbrosis and/or calciﬁcation are
predominant mechanisms of stenosis.
MEDICAL TREATMENT OF AORTIC STENOSIS
An important question is that, because no medical
treatment has been effective in slowing progression
of aortic stenosis, is treatment possible? It is of in-
terest, and not surprising, that levels of LpPLA2 are
associated with slower progression only in mild,
but not moderate/severe, aortic stenosis. Capoulade
et al. (2) speculate that early aortic stenosis is lipid-
mediated, and therefore associated with LpPLA2,
and more advanced aortic stenosis is associated with
calciﬁcation, and therefore is not associated with
LpPLA2.
In light of efﬁcacy of “statins” in treatment of
atherosclerotic coronary disease, why are statins
ineffective in slowing progression of aortic stenosis
(11)? One possibility is that trials of statins in aortic
stenosis have targeted patients with moderate/severe
stenosis, and not mild stenosis. Another explanation
may involve consequences of reduction of LDL in
unstable plaques in blood vessels, versus effects onthe aortic valve. In unstable plaques, reduction of
LDL with statins results in reduction of lipids and
inﬂammatory cells, with replacement by ﬁbrous tis-
sue (and perhaps calcium). These changes in compo-
sition of the vessel reduce the risk of plaque rupture.
Similar structural changes may occur in the aortic
valve: reduction of LDL may reduce lipids and in-
ﬂammatory cells, with replacement by ﬁbrous tissue.
A key point is that functional consequences of
these tissue changes may differ profoundly: ﬁbrosis
probably is protective in the unstable plaque, but
harmful in the aortic valve. We do not know whether
these observations and speculation are pertinent
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36to the association of LpPLA2 with progression of
aortic stenosis. It is challenging to identify a speciﬁc
mechanism that may explain failure of treatment
with LpPLA2 in acute coronary syndrome and stable
ischemic heart disease versus prediction of efﬁcacy
of treatment in aortic stenosis.
CONCLUSIONS
It seems premature to consign Lp-PLA2 as a target for
ﬁbrocalciﬁc aortic valve stenosis, especially keeping
in mind the results of the VISTA-16 trial, which
showed an increased incidence of myocardial infarc-
tion. One would be reluctant to treat patients with
a secretory phospholipase A2 inhibitor (varespladib),with the goal of slowing progression of aortic stenosis
but with the possibility of increasing the risk of
myocardial infarction (7). A trial with darapladib to
slow progression of aortic stenosis may have fewer
safety concerns. Further work is needed to elucidate
the role of Lp-PLA2 in the pathophysiology of aortic
stenosis—to establish its role as a biomarker (i.e., a
friend with a warning), or a foe with potential as a
therapeutic target.
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